Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1986 1
1987 1
1988 4
1989 5
1990 4
1991 13
1992 4
1993 17
1994 14
1995 9
1996 7
1997 5
1998 9
1999 7
2000 17
2001 15
2002 8
2003 9
2004 8
2005 13
2006 10
2007 14
2008 14
2009 20
2010 9
2011 14
2012 12
2013 12
2014 7
2015 11
2016 14
2017 13
2018 14
2019 18
2020 16
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

356 results
Results by year
Filters applied: . Clear all
Page 1
siRNA vs. shRNA: similarities and differences.
Rao DD, Vorhies JS, Senzer N, Nemunaitis J. Rao DD, et al. Among authors: nemunaitis j. Adv Drug Deliv Rev. 2009 Jul 25;61(9):746-59. doi: 10.1016/j.addr.2009.04.004. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19389436 Review.
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH. Antonia SJ, et al. Among authors: nemunaitis j. J Thorac Oncol. 2019 Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20. J Thorac Oncol. 2019. PMID: 31228626 Free article. Clinical Trial.
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Gogineni V, et al. Among authors: nemunaitis j. J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021. J Cancer. 2021. PMID: 33391401 Free PMC article. Review.
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Among authors: nemunaitis j. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. Hassan R, et al. Among authors: nemunaitis jj. J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26. J Clin Oncol. 2020. PMID: 32213105 Clinical Trial.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. Reilley MJ, et al. Among authors: nemunaitis j. J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5. J Immunother Cancer. 2018. PMID: 30446007 Free PMC article. Clinical Trial.
356 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page